For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

For individuals with chronic lung conditions, the winter season and the current cold snap poses significant challenges.

For individuals with chronic lung conditions, the winter season and the current cold snap poses significant challenges. We ...

Let’s explore the common causes of COPD and the science behind this serious disease ... These fuels release harmful smoke and ...

COPD and asthma devices are crucial in the management and treatment of respiratory diseases, providing relief and improving the quality of life for patients. These devices range from inhalers to ...

around 90% of users have poor inhaler technique. "Inhalation flow rate, duration of inhalation, and poorly timed actuation are common mistakes. "The inability of patients to take the correct dose ...

“Pharmaceutical companies should not be able to use reformulating as an excuse to sidestep their promises to patients.” Twenty-five million Americans with asthma and 16 million Americans with COPD ...

.In December 2024:- AstraZeneca- A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect ...

A RECENT study examining real-world COPD treatment outcomes has highlighted safety concerns regarding single-inhaler triple therapy compared to the long-acting beta2-agonist (LABA) and inhaled ...